skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Milnacipran: recent findings in depression

Other

(2359) Views  (439) Full article downloads

Authors: Guest editors: Stuart Montgomery (London, UK) and Mike Briley (Castres, France)

Published Date August 2010 Volume 2010:6(Supplement 1) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/NDT.S11772

EDITORIAL FOREWORD

Page 1  
Milnacipran: recent findings in depression 
Stuart Montgomery (London, UK) and Mike Briley (Castres, France)

REVIEWS

Page 3  
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran 
Philippe Courtet (Montpellier, France)

Page 9  
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran 
Peter Hofmann (Graz, Austria)

Page 17 
Antidepressant therapy with milnacipran and venlafaxine 
Lucilla Mansuy (Toulouse, France)

Page 23 
Milnacipran: a unique antidepressant? 
Siegfried Kasper and Gerald Pail (Vienna, Austria)

 

This supplement is based on a symposium that took place at the 9th International Forum on Mood and Anxiety in Monte Carlo in November 2009 and is supported by an unconditional education grant from Pierre Fabre Médicament.






 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran


Readers of this article also read:

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Editorial Foreword - Milnacipran: recent findings in depression
Antidepressant therapy with milnacipran and venlafaxine
Milnacipran: a unique antidepressant?
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
The importance of norepinephrine in depression
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Is an alcoholic fixative fluid used for manual liquid-based cytology accurate to perform HPV tests?